Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vivos Therapeutics (VVOS)
NASDAQ:VVOS
RESEARCH TOOLSreports
Holding VVOS?
Track your performance easily
VVOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.91 - $9.14
Previous CloseN/A
Volume144.69K
Average Volume (3M)280.97K
Market Cap
$35.04M
Enterprise Value$12.60M
Total Cash (Recent Filing)$1.25M
Total Debt (Recent Filing)$525.00K
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Mar 27, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.95
Shares Outstanding5,889,520
10 Day Avg. Volume354,153
30 Day Avg. Volume280,973
Standard Deviation1.03
R-Squared0.11
Alpha0.00432
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.70
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue0.86
Enterprise Value/Gross Profit1.52
Enterprise Value/Ebitda-1.12
Forecast
1Y Price Target
$6.30Price Target Upside5.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Vivos Therapeutics News
PremiumCompany Announcements
Vivos Therapeutics Reports Revenue Growth and Strategic Milestones
Ownership Overview
1.24%
Insiders
0.30% Mutual Funds
<0.01% Other Institutional Investors
98.17% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
VVOS FAQ
What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $1.91 and its highest was $9.14 in the past 12 months.
What is Vivos Therapeutics’s market cap?
Vivos Therapeutics’s market cap is $35.04M.
When is Vivos Therapeutics’s upcoming earnings report date?
Vivos Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 68 days.
How were Vivos Therapeutics’s earnings last quarter?
Vivos Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.655 by $0.255.
Is Vivos Therapeutics overvalued?
According to Wall Street analysts Vivos Therapeutics’s price is currently Undervalued.
Does Vivos Therapeutics pay dividends?
Vivos Therapeutics does not currently pay dividends.
What is Vivos Therapeutics’s EPS estimate?
Vivos Therapeutics’s EPS estimate is -0.4.
How many shares outstanding does Vivos Therapeutics have?
Vivos Therapeutics has 5,889,520 shares outstanding.
What happened to Vivos Therapeutics’s price movement after its last earnings report?
Vivos Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.655. Following the earnings report the stock price went down -8.974%.
Which hedge fund is a major shareholder of Vivos Therapeutics?
Currently, no hedge funds are holding shares in VVOS
---
Company Description
Vivos Therapeutics
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment of sleep-disordered breathing including mild-to-moderate obstructive sleep apnea resulting from underdeveloped upper and lower jaws.
---
VVOS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth, improved gross margins, and strategic expansions. However, increased net loss and cash burn, along with decreased VIP enrollment revenue, are notable challenges. The sentiment is balanced with positive growth countered by financial losses.Read More>---
VVOS Stock 12 Month Forecast
Average Price Target
$6.30
▲(5.88% Upside)
Technical Analysis
Senseonics Holdings
―
OrthoPediatrics
―
Assertio Therapeutics
―
Evolus
―
Myomo
―
VistaGen Therapeutics
―
Best Analysts Covering VVOS
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+19.16%
reiterated a buy rating 2 months ago
Copying Lucas Ward's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +19.16% per trade.
---